全文获取类型
收费全文 | 4591篇 |
免费 | 308篇 |
国内免费 | 49篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 195篇 |
妇产科学 | 127篇 |
基础医学 | 577篇 |
口腔科学 | 52篇 |
临床医学 | 272篇 |
内科学 | 943篇 |
皮肤病学 | 190篇 |
神经病学 | 355篇 |
特种医学 | 157篇 |
外科学 | 834篇 |
综合类 | 87篇 |
预防医学 | 298篇 |
眼科学 | 84篇 |
药学 | 436篇 |
中国医学 | 31篇 |
肿瘤学 | 265篇 |
出版年
2023年 | 27篇 |
2022年 | 77篇 |
2021年 | 131篇 |
2020年 | 64篇 |
2019年 | 109篇 |
2018年 | 115篇 |
2017年 | 86篇 |
2016年 | 125篇 |
2015年 | 143篇 |
2014年 | 162篇 |
2013年 | 232篇 |
2012年 | 308篇 |
2011年 | 282篇 |
2010年 | 191篇 |
2009年 | 154篇 |
2008年 | 214篇 |
2007年 | 236篇 |
2006年 | 209篇 |
2005年 | 230篇 |
2004年 | 150篇 |
2003年 | 191篇 |
2002年 | 178篇 |
2001年 | 73篇 |
2000年 | 89篇 |
1999年 | 87篇 |
1998年 | 41篇 |
1997年 | 24篇 |
1996年 | 27篇 |
1994年 | 21篇 |
1993年 | 24篇 |
1992年 | 60篇 |
1991年 | 56篇 |
1990年 | 31篇 |
1989年 | 43篇 |
1988年 | 49篇 |
1987年 | 46篇 |
1986年 | 34篇 |
1985年 | 38篇 |
1984年 | 29篇 |
1983年 | 36篇 |
1982年 | 34篇 |
1979年 | 20篇 |
1977年 | 21篇 |
1976年 | 25篇 |
1975年 | 29篇 |
1974年 | 29篇 |
1973年 | 24篇 |
1971年 | 27篇 |
1970年 | 31篇 |
1969年 | 27篇 |
排序方式: 共有4948条查询结果,搜索用时 15 毫秒
1.
Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted important steps where we need to take precautions before starting tofacitinib. 相似文献
2.
Jai Bhagwan Sharma 《The Indian journal of tuberculosis》2021,68(3):389-395
AimsTo demonstrate a new laparoscopic sign “Sharma's Parachute sign” in abdominopelvic tuberculosis in women with infertility.MethodsA total of 104 women who were diagnosed to have abdominopelvic tuberculosis, on endometrial sampling or on laparoscopy were enrolled in this ongoing study on tuberculosis in infertility. A new laparoscopic “Sharma's parachute sign” was looked for in these cases on laparoscopy.ResultsThe mean age, pairty and duration of infertility was 27.6 years, 0.58 and 4.1 years respectively. Menstrual dysfuction were common especially hypomenorrhoea (34.61%), oligomenorrhoea (36.53%) along with constitutional symptoms and abdomino pelvic pain or lump. Diagnosis of abdominopelvic tuberculosis was made by identification of acid fast bacilli (AFB) on microscopy or culture of endometrial aspirate or peritoneal biopsy or positive gene Xpert or positive polymerase chain reaction (PCR) or histopathological demonstration of epithelioid granuloma on endometrial or peritoneal biopsy, various laparoscopic findings on pelvic and abdominal organs were tubercles and shaggy areas (white deposits, caseous nodules encysted ascites, abdominal and pelvic adhesions, tubal findings (hydrosalpinx, pyosalpinx, beaded or calcified tubes). A new “Sharma's parachute sign”in which ascending colon was totally adherent to anterior abdominal wall with its mesocolon looking like an open parachute with small caseous nodule was seen in 11 (10.5%) cases.ConclusionDiagnostic laparoscopy is an important investigation for abdominopelvic tuberculosis showing various adhesions including new parachute sign. 相似文献
3.
4.
5.
6.
Aditya Kelkar Caroll Webers Rohit Shetty Jai Kelkar Nikhil Labhsetwar Abhishek Pandit Madhulika Malode Sayali Tidke 《Indian journal of ophthalmology》2020,68(10):2143
Purpose:To evaluate the rate of compliance and the reasons for loss to follow-up in Indian patients with diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) being treated with anti-vascular endothelial growth factor (VEGF) therapy.Methods:This was a retrospective single-center study. Patients with DME, AMD, or RVO were eligible if they initiated anti-VEGF therapy between January 2013 and December 2017. Patients'' data were obtained from hospital electronic records, including the number of injections received, visits, details of follow-up, missed appointments, and reasons for loss to follow-up (>365 days).Results:A total of 648 patients were eligible for the study, of which 334 (51.54%) patients were lost to follow-up. Overall, 343 (64.96%) were males and the overall mean (SD) age was 66.40 (7.44) years. A total of 376 (58.0%) patients had a history of diabetes and 364 (56.2%) patients had a history of hypertension. Further, 127 (38.0), 112 (33.5), and 95 (28.4) had DME, AMD, and RVO, respectively and were lost to follow-up. The most commonly reported reason for loss to follow-up was “non-affordability” (n = 120; 41.1%) followed by “no improvement in vision” (n = 83; 28.4%). “No improvement in vision” (42.2%) and “non-affordability” (37.5%) were higher among patients with DME. No association was found in gender- and treatment-wise distribution of reasons for loss to follow-up.Conclusion:The results showed that around half of the patients with DME, AMD, and RVO were lost to follow-up to intravitreal anti-VEGF therapy, and the most common factors were “non-affordability” and “no improvement in vision.” 相似文献
7.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献8.
9.
10.
YS Nagar S Singh V Sawlani L Pal K Dimri P Lal 《Journal of Medical Imaging and Radiation Oncology》2005,49(2):160-162
A rare case of an advanced primary broad ligament carcinoma is discussed, with a review of the literature regarding its incidence, presentation and management. This patient showed a complete response to adjuvant cisplatin-based chemotherapy following panhysterectomy and is presently without any evidence of disease, 15 months after completion of her treatment. 相似文献